5 Minutes Read

China to introduce second COVID vaccine booster for elderly and high-risk groups

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

China has announced that it will begin distributing a second vaccine booster shot against COVID-19 to high-risk groups and seniors citizens.

China’s National Health Commission (NHC) on Wednesday announced that it will begin distributing a second vaccine booster shot against COVID-19 to high-risk groups and seniors citizens above the age of 60.

According to the NHC statement, individuals with serious underlying illnesses and those with poor immunity are eligible to receive the second shot. There must be a six-month interval between the first and second booster doses, it added.

China has been trying to expedite vaccinations for people over 60 since it prepped to substantially loosen severe COVID-19 prevention measures earlier this month.

After three years of enforcing some of the most stringent virus restrictions in the world, the Chinese government made the unexpected announcement earlier this week that it was eliminating several of the restrictions.

Protests over the curbs last month in Beijing and other cities turned into calls for leader Xi Jinping and the Communist Party to step down, a degree of popular discontent unseen in decades.

Also read: China axes travel tracking app in latest easing of COVID curbs

While met with relief, the relaxation has also sparked concerns about a new wave of infections potentially overwhelming health care resources in some areas. The loosening of restrictions resulted in a substantial decline in testing but cases still seem to be rising quickly with many people conducting tests at home and avoiding hospitals.

Without asymptomatic cases being counted, China reported just 2,249 “confirmed” infections Wednesday, bringing the nation’s total to 369,918 — more than double the level on Oct. 1. It has recorded 5,235 deaths — compared with 1.1 million in the United States.

However, the government-provided statistics from China have not been independently validated, and it has been questioned if the Communist Party in power has attempted to reduce the number of cases and fatalities.

Also read: China COVID situation: Long queues at fever clinics as country mulls expanding hospitals, ICUs

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Malaria booster vaccine shows up to 80% efficacy: Lancet study

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

R21/Matrix-M, licensed to Serum Institute of India, previously demonstrated high-level efficacy of 77 percent over the following 12 months in young west African children in 2021.

A malaria vaccine booster shot at one year following a primary three-dose regime maintained high efficacy of 70-80 percent against the disease, according to a study published in The Lancet Infectious Diseases journal.

Researchers from the University of Oxford, UK and colleagues reported the findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-M.

The vaccine, licensed to Serum Institute of India, previously demonstrated high-level efficacy of 77 percent over the following 12 months in young west African children in 2021.

Also read: Over 47% antibiotic formulations used in India in 2019 unapproved: Lancet study

In their latest findings, the researchers found that a vaccine booster dose at one year following a primary three-dose regime continued to meet the World Health Organization’s Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75 percent efficacy.

A total of 450 participants aged five to 17 months were recruited from Burkina Faso, with 409 receiving the booster.

The participants were randomly assigned to three groups, with the first two groups receiving the R21/Matrix-M vaccine as a booster and the third a rabies vaccine as the control group.

Each child received the same booster vaccination as their primary series of vaccinations. Doses were administered in June 2020, largely prior to the peak malaria season.

The study reports a vaccine efficacy of 80 percent in the higher-dose adjuvant group, and 70 percent in the lower dose adjuvant group, over 12 months of follow-up.

Also read: High cholesterol and weight, reduced physical stamina may signal long COVID: Lancet study

Antibody levels were restored to similar levels as those following the primary vaccinations 28 days after the booster doses were administered, the researchers said. No serious adverse events related to the vaccine were noted, they said.

“It is fantastic so see such high efficacy again after a single booster dose of vaccine. We are currently part of a very large phase III trial aimed at licensing this vaccine for widespread use next year,” said Halidou Tinto, the trial Principal Investigator.

“We are delighted to find that a standard four dose immunisation regime can now, for the first time, reach the high efficacy level over two years that has been an aspirational target for malaria vaccines for so many years,” said Professor Adrian Hill, from the University of Oxford.

The trial has been extended for another two years to assess if further booster doses will be necessary to maintain high efficacy over time.

Results from the key ongoing Phase III licensure trial to assess large-scale safety and efficacy in 4,800 children aged five to 36 months across four African countries, are also expected later this year.

Also read: Second-hand smoke 10th biggest risk factor for cancer: Lancet study

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

COVID booster shot can now be taken 6 months after second dose

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

The government has now reduced the gap between the second COVID jab and the so-called precaution (booster) dose from nine months to six months for all adults in India.

The booster dose gap has been reduced from nine months to six months for all adults, according to the latest statement released by Rajesh Bhushan, Secretary of the National Health Mission.

The National Technical Group on Immunisation has recommended the duration between the second and precautionary doses be revised from the existing nine months or 39 weeks to six months or 26 weeks.

ALSO READ | Coronavirus in India: 23% spike recorded in daily COVID-19 cases, Maharashtra’s tally rises by 104%

Precaution doses for beneficiaries in the 18-59 years category will be given after completion of six months from the date of administration of the second COVID-19 dose at private COVID vaccination centres. Beneficiaries aged above 60 years and frontline and healthcare workers too can get their booster shots six months post the second jab.

Precaution doses were made available to all adults from April 10, however they were permitted to take it only nine months after their second dose.

While the move was welcomed, sources had suggested that the time gap was likely to be reduced.

When the precaution dose for all was announced on April 8, Serum Institute of India’s CEO Adar Poonawalla had welcomed the move. However, he too had suggested that the gap of nine months was a bit too long and the government consider reducing it to six.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Dr Reddy’s looks to sell Sputnik Light as ‘universal booster,’ to seek DGCI nod by July

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

A universal booster is a vaccine that can be taken after any shot — be it Covishield or Covaxin. Dr Reddy’s has promised competitive pricing for the now Made-in-India COVID vaccine. The current pricing of Sputnik V is Rs 995 plus taxes per dose.

Dr Reddy’s Laboratories is hoping to go to a regulator for its single-dose Sputnik Light jab as booster dose for approvals by June-end or early July, a senior official of the city-based drug-maker said on Thursday. Deepak Sapra, CEO (Active Pharmaceutical Ingredients and Services) of Dr Reddy’s, told reporters that the company has currently put its Sputnik M, a COVID-19 vaccine for children (12-17 years of age) on the backburner, and is prioritising Sputnik Light, the price of which is being reworked.

We are currently in the midst of clinical trials for Sputnik Light as a universal booster, which means that anybody who has taken any vaccine — be it Covishield or Covaxin — can take Sputnik Light as a universal booster if we get a favourable result in our clinical trials. For this, we expect to go to the regulator towards the end of June or early July, Sapra said.

Also read: Russia’s Sputnik V effective against COVID-19 in HIV positive patients: Lancet

The Drugs Controller General of India (DCGI) in February granted approval to the single-shot Sputnik Light vaccine for restricted use in emergency situation in India. In September 2020, Dr Reddy’s partnered with the Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V and distribute the vaccine in India. In April 2021, the DCGI granted approval to the two-dose Sputnik V vaccine for restricted use in emergency situation in India.

He said the drug major has sold 1.2 million doses of Sputnik V vaccine in India so far. Replying to a query on the pricing of Sputnik vaccines, he said they were working on it and it would be in line with the competition.

Also read: Sputnik V Covid vaccine shows higher Omicron-specific antibodies than Pfizer: Study

Pricing to be competitive

“The idea is to make it competitive or market-driven otherwise. The other thing is when we launched Sputnik earlier, it was getting imported from Russia. The product that is now available for booster is made in India. Pricing will be competitive in line with the market conditions,” he said. The current pricing of Sputnik V is Rs 995 plus taxes per dose. The official further said the company is filing for regulatory approvals for its COVID-19 portfolio of medicines in several countries where there is a surge.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Biological E seeks emergency use authorisation for Corbevax as booster COVID-19 dose for adults

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

At present, Corbevax is being used to inoculate children in the 12 to 14 age group. Biological E submitted an application to Drugs Controller General Of India (DCGI) seeking emergency use authorisation (EUA) for the Corbevax vaccine as a booster COVID-19 shot for adults fully vaccinated with Covishield or Covaxin.

Biological E has submitted an application to India’s drug regulator seeking emergency use authorisation (EUA) for its COVID-19 vaccine Corbevax as a booster dose in adults fully vaccinated with Covishield or Covaxin, sources said on Wednesday.

The Drugs Controller General Of India (DCGI) had already approved Corbevax, India’s first indigenously developed RBD protein subunit vaccine, for restricted use in emergency situations for those aged 5 and above.

Currently, it is being used to inoculate children in the 12 to 14 age group. According to the EUA application submitted to DCGI, Biological E in a phase-3 placebo-controlled clinical study, based on the drug regulator’s nod, has evaluated the safety and immunogenicity of Corbevax as a single-dose booster in COVID-negative adults fully vaccinated with either Covishield or Covaxin.

Also Read: Facemasks can reduce COVID-19 severity, pressure on health systems, study confirms

The study was conducted on 416 subjects aged 18 to 80 who were vaccinated with two doses of either Covaxin or Covishield with the last jab administered at least six months prior to giving the booster dose of Corbevax. “The results showed a significant boost in immunogenicity in terms of neutralizing antibodies after 28 days when compared with placebo cohort in both Covishield and Covaxin arms.

“The safety profile of Corbevax was found similar to that of the earlier clinical trials,” an official source told an official source told PTI,  quoting the Hyderabad-based firm as having mentioned in the EUA application.

The firm said, “We are now submitting the marketing authorization application for grant of permission Corbevax for restricted use in an emergency situation as a booster dose at six months after completion of primary immunization with two doses of Covishield or Covaxin in individuals aged 18 years and above.”

As of now, the precaution dose is of the same COVID-19 vaccine used for administering the first and second doses.

India began administering precaution doses of COVID vaccines to healthcare and frontline workers and those aged 60 years and above with comorbidities from January 10.

Also Read: WHO wants China to restrategise as zero COVID policy ‘not sustainable’; China dismisses criticism

The comorbidity clause was removed in March, making all people aged above 60 years eligible for the precaution dose of COVID vaccine.

India on April 10 began administering precaution doses of COVID-19 vaccines to all aged above 18 years at private vaccination centres.

All those above the age of 18 who have completed nine months after the administration of the second dose are eligible for the precaution dose.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Gap between 2nd dose of COVID vaccine, precaution dose to be reduced to 6 months soon, says report

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

India began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from Jan 10. The comorbidity clause was later removed making all people aged above 60 eligible for the precaution dose in March.

The government is likely to soon reduce the gap between the second dose of COVID-19 vaccine and the precaution dose from the current nine months to six months, official sources said on Wednesday. A recommendation on lessening the gap is expected to be made by the National Technical Advisory Group on Immunisation (NTAGI) which is set to hold a meeting on April 29.

Studies at ICMR and other international research institutions have suggested that antibody level wanes after about six months from the primary vaccination with both doses and giving a booster increases the immune response. All those above the age of 18 who have completed nine months after the administration of the second dose are eligible for the precaution dose.

“Taking into account the scientific evidence and findings of the studies done here and internationally, the gap between the second dose of COVID-19 vaccine and the precaution dose will most likely be reduced from the current nine months to six months soon. A final decision will be taken based on the recommendations by the NTAGI which is set to meet on Friday,” a source in the know of the developments told PTI.

India began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10. The government removed the comorbidity clause making all people aged above 60 eligible for the precaution dose in March.

According to health ministry data, 5,17,547 precaution doses have been administered in the age group 18-59 years so far. Besides, 4736567 healthcare workers, 74,47,184 frontline workers and 1,45,45,595 individuals aged 60 and above have taken the precaution shot.

India on April 10 began administering precaution doses of COVID-19 vaccines to all aged above 18 years at private vaccination centres.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Vaccine fatigue? Complacency, confusion, fear behind reluctance to take Covid booster, says experts

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

As India’s Covid graph inches upwards, not enough people are getting their booster shots. Data shows that Indians could be grappling with vaccine fatigue, a reluctance to take a booster shot that experts attribute to a combination of fear, confusion and misinformation.

With only 4.64 lakh people taking their third Covid jab since April 10, Indians could be grappling with vaccine fatigue, a reluctance to take a booster shot that experts attribute to a combination of fear, confusion and misinformation.

As India’s Covid graph inches upwards, not enough people are getting their booster shots. Among the reasons for the apparent lethargy are the fear of adverse effects, the view that Covid is now a mild infection and doubts over whether a precaution dose is indeed useful, said scientists, public health experts and industry insiders.

According to virologist Dr T Jacob John, vaccine fatigue has set in, also because the “cacophony of new experts” has been confusing. “I get a number of questions for clarification on booster doses, hence I know that the educational activity’ of the government that wants to prevent COVID-19 deaths, hospitalizations and severe symptoms by completing the vaccination schedule in highly vulnerable people was more confusing than clarifying,” John told PTI.

For a long time, people were told that full vaccination meant two doses so the term precaution dose added to the confusion, added the former director of the Indian Council for Medical Research’s Centre of Advanced Research in Virology. Vaccine fatigue, experts explained, is when people do not take proactive action to get vaccinated.

Last week, Serum Institute of India (SII) CEO Adar Poonawallah, whose company manufactures the Covishield vaccine, said they have a lot of unsold inventory. “We stopped production on December 31, 2021. Currently, we are sitting on over 200 million doses. I have offered this to anyone willing to pick them up for free. But there hasn’t been a good response to that also.”

“It seems there is vaccine fatigue among the people now as even after the price was slashed to Rs 225, there has been no major uptake,” Poonawalla said at the Times Network India Economic Conclave. The firm has slashed the price from Rs 600 to Rs 225 a dose.

In the view of Praveen Sikri, Ikris Pharma Network CEO, people are questioning the need for a precaution dose, thinking the last wave was mild. “The large number of misinformation campaigns launched by anti-vaxxers such as campaigns about children developing liver failure and developing clots and people dying of vaccines had played a role in the reluctance. Also, because the Omicron wave has been not a very dangerous one, so it is adding to the vaccine fatigue,” said the pharma industry insider who has closely been following India’s Covid trajectory.

He added there is need to counter this by developing more conversations around vaccines, letting people becoming involved in decision making. It is important to let people know that countries that have not had adequate vaccination programmes or have had vaccines which are not effective are suffering very severely now due to Covid, Sikri said. Factual information with believable evidence will allay the anxieties of people, John added.

“When the risk from disease has markedly reduced as the epidemic is over, people worry about the risk of serious AEFI (adverse event from immunisation). Once vaccine hesitancy has been created, it is going to be tough to overcome it Prevention is always better than cure,” he said.

Dr Ankita Baidya, consultant, infectious disease, at the Manipal Hospital in Delhi, said “people are coming forward with complaints following vaccination, particularly the booster dose recommended recently. As an infectious disease physician, I would like to stress that malaise is a common side effect of vaccination. But I have also seen that summers are ongoing and there are some components of psychological factors that after booster doors people are experiencing such kind of fatigue.”

“Even if it is there, it should not be long-lasting. If someone feels fatigued or malaise and has body ache in the initial days after vaccination, this could be just a post-vaccination mild side-effect of the vaccine and it will go away,” she said. Counselling over the usefulness of a booster dose is important, Baidya stressed.

Dr Vikas Deswal, senior consultant, internal medicine, at Gurgaon’s Medanta Hospital concurred, saying there is lack of understanding of the benefits of the booster doses.

“Many believe that double vaccination is enough. A sense of complacency has settled in. But booster doses are very important because they keep us immunised. This ensures that even if the virus attacks us, there are enough antibodies to ensure that the infection is mild. The only way to counter vaccine fatigue is to constantly explain the benefits of the booster dose, make it more easily accessible and available,” he said.

While experts debate the reasons for vaccine fatigue, Neha Sharma, a Noida-based IT professional, said her menstrual cramps had worsened after she took her first and second jabs. “Though the doctor told me that it is unrelated to the vaccine, I am still scared to take the third dose.”

“Also I feel that now the Omicron driven infection is getting milder, so Covid is akin to seasonal flu. Why complicate things by taking a third dose,” she said. Amna Hasan, a resident of Lucknow based homemaker, added that she has just started feeling better after contracting Covid twice.

“Why take a chance by inducing the same dead virus in my body again,” Hasan, who was infected in both the second and third wave of COVID-19, said. Shaunak Sharma, a Noida based engineer, has no plans to take the precaution dose either.

“We have developed immunity from COVID-19 in the past two years, I recently got my antibodies tested and had enough so though my precaution dose is not due for the next few months. I don’t plan to take precaution dose.” he said. On April 10, India began administering precaution doses of COVID-19 vaccines to all aged above 18 years at private vaccination centres.

An estimated 4,64,910 precaution doses have been administered till Tuesday morning, according to Union Health ministry data . Of these, about half, 2,46,962 were administered in the 18-59 age group between April 20-26. On Tuesday, India recorded 2,483 new coronavirus infections.

The daily positivity rate was recorded as 0.55 percent and the weekly positivity rate as 0.58 percent, according to the ministry. Certain areas are reporting a higher positivity rate. Delhi, for instance, reported 1,011 fresh cases on Monday and a positivity rate of 6.42 percent.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

Haryana CM announces free Covid booster shots for 18-59 age group

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

In a surprise move, Haryana CM Manohar Lal Khattar announced free Covid booster shots for beneficiaries in the age group of 18 to 59 years. With 1.2 crores people estimated to benefit, this move is expected to cost 300 crores on state’s exchequer.

Haryana Chief Minister Manohar Lal Khattar Monday announced free Covid vaccine booster shots for beneficiaries in the age group of 18 to 59 years, according to an official statement. The eligible people can get the booster shot, which currently costs Rs 250 plus service charges, free of cost at any government hospital or dispensary.

It said there are about 1.2 crore such beneficiaries in Haryana and the total cost of about Rs 300 crore on their booster doses will be borne by the state from the COVID Relief Fund. The CM further said that in addition to Covid vaccination, adhering to COVID-19 guidelines is the biggest tool in the fight against the pandemic.

In view of the recent surge in cases in a few districts, particularly in Gurugram and Faridabad, Chief Minister Khattar appealed to people to wear masks and ensure strict adherence of Covid-appropriate behaviour like washing hands frequently, according to the statement.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

COVID booster dose: Reduce time gap to 6 months from 9, Serum Institute tells govt

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

Serum Institute of India CEO Adar Poonawalla also pitched for a global pact for vaccine utilisation, while noting that India and SII faced severe reputation damage when export of COVID vaccine was banned for nearly two months during the lethal second wave.

Vaccine major Serum Institute of India (SII) has appealed to the government to reduce the gap between the second and booster dose to six months from nine months at present to safeguard people against emerging COVID variants, according to its CEO Adar Poonawalla. Recalling that they could not meet the commitment of exporting vaccines in the first quarter of 2021 due to “so much noise from public and the Opposition,” Poonawalla on April 12 also pitched for a global pact for vaccine utilisation.

He noted that India and SII faced severe reputation damage when export of COVID vaccine was banned for nearly two months during the second COVID wave. “The uptake (for precaution dose) right now is a bit slow as we have a rule that you have to wait for nine months between dose two and dose three. We have appealed to the government and the experts, who are having discussions regarding the matter, to reduce this period to six months,” he said during an AIMA event here.

Also read: UN chief Antonio Guterres warns of large COVID outbreaks in Asia, says pandemic far from over

Poonawalla noted that reducing the timeframe would give “real relief” to the people who want to travel abroad. If you have taken a dose in August then only you are eligible for a booster dose, so we need to reduce that gap to six months. Many citizens would be able to take the dose then,” he said. He pointed outs that all across the world, the gap between second dose and booster shot is six months or less.

When asked if the company is in discussions with the government on the issue, Poonawalla replied in the affirmative. “The experts and the government need to have their own discussions. We are just highlighting that this is the need that everyone has voiced from a practical standpoint from wanting to travel. So we have proposed a six month gap.”

Also read: COVID shot for less than Rs 150 likely by yearend; Epygen Biotech gets govt funding for new vaccine

Against this backdrop, he also pointed out that the world faces a choice between lockdowns and booster shots. “It is so important to boost with whichever vaccines you can get your hands on, because that will ensure that you are protected and we reduce as a nation or even as states the chances of future lockdowns and disruptions… that’s why I’ve been telling the government that please, for god’s sake, reduce the gap from nine months to six months,” Poonawalla said.

Lauding the government for having brought in a booster policy, he said SII has brought down the price of Covishield from Rs 600 per shot to Rs 225 as it wants to make it affordable and accessible for people. He advised all eligible people to take the shot in order to safeguard against future COVID variants which were emerging in different locations.

Also read: COVID-19 vaccine: Covishield, Covaxin price cut to Rs 225 for private hospitals

Poonawalla said the Pune-based vaccine major is giving compensation to private hospitals by way of three doses to adjust on the reduced prices. “So any hospitals that have old stock at Rs 600, they don’t have to sell at a loss, we give them more vials so they don’t go into a loss. We don’t want them to lose money on old stock,” he stated.

Poonawalla said he is working on a global pandemic treaty, which espouses harmonisation of regulatory standards during a global pandemic situation, at the Davos summit next month. “We need to address not only as a nation… We have to have in a pandemic situation global harmonisation of regulatory standards. We need to have mutual recognition of vaccine certifications. We need to have a free flow of goods of raw materials and vaccines in a crisis so that that sharing happens,” he stated.

Also read: Sweden to give 4th COVID-19 shot to people over 65

According to him, with a global pandemic treaty, countries can always use their sovereign rights or whatever to abstain rather than relegate from it, but it would become much harder for political leaders to do that on a global stage.

“It would also make it much easier for politicians to convince their constituents in their own nations that this is the right thing to do and we’ve committed and signed up at a global level to do it,” he noted.

He noted that vaccine exports were hit during the second wave of COVID-19. “We were trying to export vaccines in the first quarter of 2021. The Opposition, government and others felt that all the vaccines should remain in India. But what we failed to communicate to them perhaps as a community was that we get a lot of reciprocity from other countries because India is the pharmacy of the world,” Poonawalla said.

Also read: COVID-19: XE variant not more severe than Omicron, says Gagandeep Kang

He further said: “And our help and support to other nations gives us a lot of other things that I won’t go into at the moment including the fact that when we needed oxygen, when we needed other things, other countries have stepped up and helped us because we supported them.”

The country should have continued giving some vaccines but there was so much noise from the public and the Opposition that the government had no choice but to agree and keep all the vaccines for India, Poonawalla stated.

“That damaged the reputation of India and Indian companies abroad who had made commitments. So all these things are sometimes not easy to convey and articulate and, you know, with the media and the public at large in a crisis it is very difficult to manage that communication. And I hope that these are some of the learnings going forward,” he added.

Also read: DCGI gives nod to phase-3 clinical trial of Covovax as booster dose in adults

Having a treaty would explain all this and give those commitments ahead of time, he said. He noted that at some point in time the Indian government helped the company to get raw materials from the US during the pandemic.

“That was not necessarily in the sense that if we had a treaty and understanding in place at the country level, it would have been automatic. And that’s what we need to get done,” he added.

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?

 5 Minutes Read

COVID-19 precaution doses to be available for all adults from April 10 at private vaccination centres on payment

KV Prasad Jun 13, 2022, 06:35 AM IST (Published)

 Listen to the Article (6 Minutes)

Summary

The precaution doses will be available on payment at private centres. 

The Union Health Ministry on Friday announced that all those aged above 18 years will be eligible for the precaution doses of the COVID-19 vaccine from April 10, 2022.

The precaution doses will be available on payment at private centres.

“All adults above the age of 18 years, who have completed nine months after the administration of the second dose, will be eligible for the precaution dose,” the Union Ministry said, adding that the precaution doses of the COVID-19 vaccine would be made available to the 18-plus population at private vaccination centres.

Adar Poonawalla, Serum Institute of India’s CEO, welcomed the government’s decision. He said it is a huge relief for all those who wanted to take the booster as a precautionary dose or for travel.

However, he said the gap of nine months between the second dose and the precaution dose was a bit too long and the government could look at a gap of six months after the second dose as well. He said his company would sell Covishield to hospitals for Rs 600.

Dr N Trehan, Chairman of Medanta, also welcomed the government’s move of making the precaution dose available to all adults from April 10. He said there is enough cynical data to show that precaution dose protects people from COVID-19 and even if they are infected the impact is minor.

“The ongoing free vaccination programme via government vaccination centres for first and second dose of the COVID-19 vaccine as well as the precaution dose for healthcare workers, frontline workers, and the 60+ years population will continue and would be accelerated,” the Union Health Ministry said.

Over 2.4 crore precaution doses have already been administered to healthcare workers, frontline workers and those above the age of 60 years. Besides, 45 percent beneficiaries in the 12-14 years age group have also received the first dose, the Ministry said.

About 96 percent of all those aged above 15 years in the country have received at least one dose of the COVID-19 vaccine, while about 83 percent of the same age group has received both doses.

(With PTI inputs)

Also Read: Sweden to give 4th COVID-19 shot to people over 65

Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout

3 Mins Read

Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter

 Daily Newsletter

KV Prasad Journo follow politics, process in Parliament and US Congress. Former Congressional APSA-Fulbright Fellow

Previous Article

Oil Fluctuates as Traders Assess China’s Vow, Unrest in Libya

Next Article

Shanghai residents turn to NFTs to record COVID lockdown, combat censorship

LIVE TV

today's market

index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -72.15
sensex ₹1,882.60 +28.30
nifty IT ₹2,206.80 +30.85
nifty bank ₹1,318.95 -14.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95
index Price Change
nifty 50 ₹16,986.00 -7.15
sensex ₹1,882.60 +8.30
nifty IT ₹2,206.80 +3.85
nifty bank ₹1,318.95 -1.95

Currency

Company Price Chng %Chng
Dollar-Rupee 73.3500 0.0000 0.00
Euro-Rupee 89.0980 0.0100 0.01
Pound-Rupee 103.6360 -0.0750 -0.07
Rupee-100 Yen 0.6734 -0.0003 -0.05
Quiz
Powered by
Are you a Crypto Head? It’s time to prove it!
10 Questions · 5 Minutes
Start Quiz Now
Win WRX (WazirX token) worth Rs. 1500.
Question 1 of 5

What coins do you think will be valuable over next 3 years?

Answer Anonymously

Should Elon Musk be able to buy Twitter?